SABCS 2018 — Hormonal risk factors for breast cancer, updated with new evidence


  • Actualités des congrès en Oncologie
L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte. L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte.

Takeaway 

  • New evidence on hormones and breast cancer risk clarifies associations with endogenous hormones, oral contraception, intrauterine devices (IUDs), parity, and lactation. 

Highlights

  • Data have shown that estrogens, testosterone, and insulin-like growth factor I (IGF-1) are associated with a modest increased risk for breast cancer in premenopausal women.
  • New data show anti-Müllerian hormone (AMH) is also associated with breast cancer risk in premenopausal women to a similar extent as other hormones.
  • Data have clearly established that testosterone, prolactin, and estrogens have a positive association with breast cancer in postmenopausal women. 
  • Combining genetic risk score, mammography density, and plasma hormone levels significantly improves breast cancer risk prediction models, such as the National Cancer Institute’s Gail model and the Rosner-Colditz model.
  • New data on oral contraception confirm older findings of modestly increased breast cancer risk, with slightly less long-term attenuation after longer duration of use than previously seen.
  • Limited data on hormonal IUDs show modest positive or null association with breast cancer risk, with less data on influence of duration of use. 
  • Regarding established association between parity and breast cancer risk: increasing parity is associated with decreasing risk for ER+ breast cancer, but increasing risk for ER breast cancer 
  • New evidence on lactation indicates increased lactation reduces risk for ERdisease.